

ZINC SUFFICIENCY AND COVID-19 MORTALITY IN SOCIALLY SIMILAR EUROPIAN POPULATIONS

Samer Singh, PhD^{1#}; Amita Diwaker, MBBS, MS²; Rakesh K. Singh, PhD³

¹Centre of Experimental Medicine & Surgery, Institute of Medical Sciences, Banaras Hindu University, Varanasi – 221005, India

²Department of Obstetrics and Gynecology, Institute of Medical Sciences, Banaras Hindu University, Varanasi – 221005, India

³Department of Biochemistry, Institute of Science, Banaras Hindu University, Varanasi – 221005, India

Address for correspondence: samer.singh10@bhu.ac.in; **ORCID ID:** <https://orcid.org/0000-0002-0921-1686>

ABSTRACT:

The effect of Zinc (Zn) supplementation or the sufficiency of populations on the occurrence of COVID-19 and associated severe illness/mortality remains unknown. There is a dearth of evidence suggesting any potential protective role for Zn supplementation in COVID-19. However, the general deficiency of Zn in populations, combined with the requirement of optimal Zn levels for immune competence and milder side effects associated with its overdosing in the healthy, have contributed to its widespread inclusion as part of general prescriptions for COVID-19 as well as an immunity booster during the COVID-19 pandemic. Over the counter purchases of Zn supplements have seen an upward trend during the pandemic. Expectedly, multiple trials are underway to ascertain/identify the positive effect of Zn supplementation on COVID-19 infection and mortality when given in combination with standard of care treatments. However, the designs of trials seem to lack the power to identify negative effects especially in the identified vulnerable groups prone to adverse outcomes. When we analyze the COVID-19 data from 23 socially similar European populations/countries with supposedly comparable confounders (population: 522.47 million; experiencing up to >150 fold difference in death rates) and stage of the pandemic from 12 March - 26 June 2020 (1st wave of infections); the populations' Zn-sufficiency status is found consistently positively correlated with COVID-19 mortality ($r(23)$: 0.7893–0.6849, p -value<0.0003) as well as infections ($[r(23)$:0.8084 to 0.5658; p -value<0.005) for the period. The known existence of a small percentage (2-6%) of adults/elderly with conditions/comorbidities in the populations susceptible to higher Zn intake/supplementation related pathologies could be suspected for the paradoxical observation. Controlled trials or retrospective analysis of the adverse event patients' data seem warranted for ascertaining the basis of the observation in uncertain terms to allow the harnessing of the full protective potential of the Zn supplementation for populations.

Key Words: COVID-19, Zinc, micronutrient, elderly, oxidative stress, redox, mortality, infection

INTRODUCTION:

Zinc (Zn) is a key micronutrient that plays an important role in immune competence and wellbeing (1). The explicit and implicit general recommendations for immune augmentation of population and COVID-19 patients by healthy diet or Zn supplementation in the supposed Zn deficient individuals as adjunctive therapy option as per 'COVID-19 treatment panel guidelines' are in place for its potential protective role in infections and other immune and oxidative stress-related conditions/pathologies relevant to COVID-19 (2-5). **A huge surge in the number of articles advocating a role for Zinc supplementation in COVID-19 treatment/management has been observed lately** (keywords '((Zinc) AND (COVID-19)) AND (treatment)' yielded 117 articles in Pubmed on 14 Jan 2021(6). Speculative benefit from Zn supplementation in COVID-19, interpretational and implementational issue with the panel guidelines regarding recommended daily dietary intake due to unavailability of reliable measures of actual deficiency in individuals or the daily dietary intake estimates, combined with the relatively milder side effect of Zn overdose in the majority of the population appeared to have fueled its widespread prescription and over-the-counter purchases. The actual figures of the total increase in Zn supplementation worldwide as a result of the COVID-19 pandemic are not in the public domain but from news articles, it may be surmised that it had already registered a surge by mid-April of 2020 and have increased in different markets/countries since then as per news reports (7-9). **However, the clinical evidence supporting any possible beneficial effect of Zinc supplementation or the ecological association studies unequivocally supporting the potential positive impact of Zn sufficiency of the population/individuals on SARS-CoV-2 caused COVID-19 disease are practically nonexistent. The push for Zn supplementation in COVID-19 also seems to stem from the observed negative impact of physiologically 'irrelevant levels' of Zinc in suppressing *in vitro* viral replications in general [REFs 10] and coronaviruses in particular [11].** Globally, Zn deficiency among populations ranges from 3-54% (12). The developed European and North American nations generally have the most sufficiency while African and Asian nations the least. Its deficiency in populations is widely associated with vulnerability to infectious diseases, chronic immune system disorders, and medical conditions (1-3,5,12,13).

The Zn levels are tightly regulated in the human body and its differential levels are maintained in various organs, tissues, and extracellular milieu including serum through a complex homeostasis mechanism. Though not always appropriate, serum levels are generally considered as reflective of Zn deficiency/sufficiency in the absence of more accurate measures and usually in combination with overt pathological features are used to diagnose pathological deficiency and subsequent recommendation/prescription of Zn supplementation or augmentation of its levels through diet modifications but not always without adverse outcome or failures in certain conditions more common in

elderly and relevant to COVID-19 adverse events, e.g., sickle cell disease, chronic kidney diseases, cardiovascular diseases (CVD) and coronary heart disease (CHD) (13-16).

We reason, if Zn levels would be playing the desired beneficial role in COVID-19, the COVID-19 mortality (and infections) would closely but negatively covary with the populations' Zn sufficiency (diet and supplementation) estimates. We endeavored to assess the null-hypothesis that Zn sufficiency/levels are not associated with COVID-19 mortality in populations. For this, socially similar European populations with higher HAQ Index, Life expectancy, Median age (17,18) similar confounders (19-23) but closely graded different Zn sufficiency/deficiency levels (12), and differential COVID-19 impact (17) offer an excellent opportunity to ascertain any potential protective role of Zn levels or its augmentation on COVID-19.

RESULTS:

When we analyze the COVID-19 incidences and mortality data (12 March to 26 June 2020) of twenty-three socially similar European populations (Total 522.47 million) with similar confounders (19-23), different Zn sufficiency/deficiency levels (12) accounting for 15.71% cases (1552 thousand cases) and 34.2% deaths (173 thousand deaths) of the total global for correlation (Pearson's) and perform regression analysis without any additional exclusion/inclusion criterion of risk factors or supposed confounders (e.g., age, sex, age distribution, comorbidities, populations' density, etc.) some interesting observations were made as outlined below:

- 1. Globally COVID-19 mortality rates positively covary with Zinc sufficiency levels:** Zinc sufficiency/deficiency levels vary across the globe (Supp. Dataset 1 – Sheet: Global Zn Suff. COVID-19 Impact). Generally, differential COVID-19 mortality rates had been observed among countries with the European and North American countries with higher HAQ Index, Life expectancy, Median age (6,7) being the worst affected. Previously, Trained-immunity (19,20), BCG vaccination (21), vitamin D (22), Zinc deficiency (23) had been associated with reduced COVID-19 mortality using early-stage pandemic data (19-23), though not without controversies for inclusion/exclusion criteria, non-matched pandemic stages, appropriateness of the data set, analysis and the loss of association with the time post-peak-of-infections (19,20,22,24). Globally the populations were exposed to COVID-19 at different time-points, had differential access to medical facilities, life-style, social-structure, preventive measures in place, supposed associations drawn from them could be tenuous due to disparate data sets. To arrive at more dependable conclusions, when pandemic phase-matched (Supp. Dataset 1 – Sheet: Death-Case Notification Rate), populations with

comparable confounders (19,21,22,24) were analyzed the COVID-19 mortality rate in socially similar populations (Boxed North America and European Union NA and EU) were found to strongly associate with their Zinc sufficiency (Supp. Dataset 1 – Sheet: Global Zn Suff. COVID-19 Impact; time-series graphics available at reference 18). Incidentally, European, North American, and South American countries reporting high mortality have been the high Zinc sufficiency countries.

- 2. Zinc sufficiency strongly and significantly correlated with COVID-19 mortality in socially similar countries:** The Zinc sufficiency in socially similar 23 European populations (Fig 1A, Supp. Dataset 1 – Sheet: Cases-Mortality-Zn Suff. Pop.) positively associated with COVID-19 mortality and infection rates (Fig. 1B-C). The mortality and infections covaried exponentially with Zn sufficiency (Fig. 1D-E). Above >92.5% Zn sufficiency, the populations experienced up to 9X higher deaths (Fig. 1D). Pearson's correlation for the most synchronized period of infections and response (26 April to 26 June, Supp. Dataset 1 – Sheet: Death-Cases Notification Rate) was strong [Table 1, Deaths per million: $r(23)= 0.7455-0.6849$, $p<0.0003$; Cases per million: $r(23)= 0.8084-0.7629$, $p<0.00002$]. Even the division of countries using >93.7% sufficiency cutoff, indicated high mortality (5.79 to 2.66X) and incidences (4.5 to 2.3-fold) in High Zn sufficiency populations (n=12) as compared to Low sufficiency (n=11).
- 3. Higher Zn sufficient socially similar countries/populations consistently reported higher COVID-19 case fatality rates (CFRs) and incidence rates:** The CFRs of different sufficiency population groups, *i.e.*, high (>93.7%, 12 countries) vs low (<93.7% 11 countries) had been essentially different and showing decline post-peak-of-infections, *i.e.*, 12 May (Fig. 1F) possibly indicative of an increase in protected population but the relative change in the CFR decrease had been lower for the higher sufficiency countries and the gap had been consistently increasing (about 16% on 26 June that become 30 % by 26 Aug 2020) (Fig. 1G).

DISCUSSION AND CONCLUSION:

Overall a general positive correlation of COVID-19 mortality and cases with Zn sufficiency levels was observed during the 1st wave of infections, which sustained till the flattening of the curves. Nevertheless, comparison of socially similar' populations/countries at similar phase/stages of the pandemic with comparable potential confounders, closely graded Zn sufficiency levels of study populations that globally accounted for 34.2% mortality (173 thousand deaths) gives confidence to the observations made. However, the use of Zn sufficiency estimates from 2005, in the absence of any recent data, as a surrogate for the current levels in populations may somewhat limit our degree of confidence in the analysis. For the sake of current analysis and discussion, it may be assumed that drastic overall changes in Zn sufficiency

levels may have not taken place, except the expected Zn sufficiency improvement with the development index and the availability of diverse foods and supplements. The surprisingly strong association between Zn sufficiency of populations with COVID-19 mortality and incidences for the whole study duration even stronger than those being hotly discussed, debated and evaluated in clinical trials [21,22,24], warrants thorough endeavors to reap the benefits of Zn supplementation by the populations without endangering few.

The observed absence of beneficial effect of Zinc sufficiency on reducing the mortality from respiratory diseases COVID-19 has the hallmarks as observed with some other respiratory diseases post-infection as well. Though Zn is supposed to protect the well-being and integrity of respiratory cells during lung inflammation and injury from respiratory tract infections and decrease the incidence of infections by regulating immune functions and response[25], the ability of zinc supplementation to help reduce the infection, severity or treatment of lower respiratory tract infections (a comorbid condition in more than 50% COVID-19 deaths) has not been unequivocally supported in all settings as per studies summarized in WHO document available in e-Library of Evidence for Nutrition Actions (eLENA) [26]. Similarly, beneficial effects of Zinc supplementation have not been observed in the case of tuberculosis which is characterized by lower circulating Zn levels [27]. A meta-analysis of Zn micronutrient supplementation was not found to augment the tuberculosis therapy outcomes as assessed at different time points (e.g., sputum-culture or sputum-smear positivity, chest x-ray clearance; death in HIV positive patients) [28]. The finding reported in a recent paper in JAMA would be pertinent here concerning Zn supplementation of HIV patients who have been also hardly hit by COVID-19 [29]. A detrimental effect of Zn supplementation on the overall survival of study participants was observed. The study using a cohort of HIV-positive alcoholic veterans endeavored to ascertain the effect of zinc supplementation on markers of mortality, the risk of cardiovascular disease, the levels of inflammation and associated microbial translocation and HIV disease progression, and finally concluded that Zn supplementation did not affect/improve the markers investigated in the study based upon its analysis of the 69% participants adhering to and completing the 18-month study. Surprisingly, a closer look at the cause of dropouts or the deceased of the study provided in the supplementary table (eTable. 'Causes of Death in the ZINC Trial by Randomized Group'), provides a glaringly different narrative. It underlines a potentially serious detrimental/negative impact of Zn supplementation on a section of HIV infected cohort, *i.e.*, Zinc supplementation positively associated with increased all-cause mortality – about 1.8 times with a 3.5-fold increase in HIV-related deaths, overdose-related deaths 4 fold, along with deaths from pneumonia and Thromboembolism [29] – conditions relevant to COVID-19 [30].

Two notions that are supposedly further contributing to the increase in Zinc supplementation for COVID-19 are, a) Zinc can block viral replication, b) patients reporting COVID-19 symptoms have lower Zinc

levels. It must be remembered here that the Zinc levels required to achieve viral replication inhibition *in vivo* are not possible without killing the host [10]. During infections and fever as a result of the natural ‘nutritional immunity’ response, the availability of cellular as well as the systemic Zn (from circulation) is reduced to impede the growth of pathogens [31]. The redistribution of Zn from circulation also seems to be a mechanism to limit the oxidative damage to peripheral tissue, if any, away from circulatory or other vital systems during infection as a result of the normal immune response or that may result from the heightened inflammatory response in severe cases leading to a localized increase in oxidative radicals.

Though the variable responsible for the observed association of Zn sufficiency and COVID-19 mortality remains unknown, we may conjure that the increased mortality observed in high Zn sufficiency populations could be contributed by the existing certain small percentage of populations with underlying conditions as a result of altered genetic composition, physiology, response to Zn supplementations/modulation [13-15,32] making them prone to display characteristic COVID-19 adverse illness as a result of increased oxygen radical generation or compromised diminished oxidative stress handling system due to their physiologies propensity to promote the pro-oxidant role of Zn on supplementation [33]. Here it may be indicated that the Zn overdose may not be uncommon in the highly impacted general aged population of the developed countries that are more receptive to supplementation with or without a prescription [34].

In conclusion, the observations presented underscore the need to undertake exploratory studies to identify and link underlying conditions that could have the potential to make certain ‘supposed’ Zn sufficient individuals prone to COVID-19 mortality. The outcomes could help devise more thorough and comprehensive Zn supplementation practices for minimizing COVID-19 mortality.

MATERIAL AND METHODS:

Study populations and Zn supplementation status: The COVID-19 incidences and mortality data (12 March to 26 June 2020) were collected from Worldometer (17). Twenty-three socially similar European populations (Total 522.47 million) with similar confounders (19-23) but different Zn sufficiency/deficiency levels (12), had registered 15.71% cases (1552 thousand cases) and 34.2% deaths (173 thousand deaths) of the total global were analyzed for correlation.

Statistical analysis: All basic statistical analysis including correlation (Pearson’s) and regression analysis were performed in Microsoft Excel. COVID-19 mortality and incidence, without applying extra exclusion/inclusion criterion of the risk factors or supposed confounders (e.g., age, sex, age distribution, comorbidities, populations’ density, etc.), were assessed for correlation with populations’ Zn sufficiency.

Interim case fatality ratio (i-CFR) for the populations/groups were calculated as '(reported deaths/reported cases)*100. P-value <0.05 is referred to as statistically significant.

Epidemiological Map display and required color manipulation: Global maps showing country-wise Zn-levels as well as COVID-19 incidence and deaths are adapted from [18]. Color scheme variations in maps were performed using 'Inkscape'.

ACKNOWLEDGEMENTS/ DISCLOSURES

Funding: No specific source of funding was utilized for the current study. However, SS acknowledges the funding support to his laboratory from the Institute of Eminence (IoE) seed grant, Banaras Hindu University.

Conflict of interest: There is no conflict of interest to disclose.

Ethical statement: The study is compliant with the ethical standards. Considering the design of the study no human or animal rights were infringed upon.

Informed consent: Considering the design of the study no informed consent was necessary.

REFERENCES:

1. Prasad, A. S. (2013). Discovery of Human Zinc Deficiency: Its Impact on Human Health and Disease. *Advances in Nutrition*, 4(2), 176-190. Available at: <https://academic.oup.com/advances/article/4/2/176/4591626>
2. Christianne de Faria Coelho-Ravagnani, Flavia Campos Corgosinho, Fabiane La Flor Ziegler Sanches, Carla Marques Maia Prado, Alessandro Laviano, João Felipe Mota, Dietary recommendations during the COVID-19 pandemic, *Nutrition Reviews*, , nuaa067, <https://doi.org/10.1093/nutrit/nuaa067>
3. Calder PC, Carr AC, Gombart AF, Eggendorfer M. Optimal nutritional status for a well-functioning immune system is an important factor to protect against viral infections. *Nutrients*. 2020;12(4):1181. Doi: 10.3390/nu12041181
4. COVID-19 Treatment Guidelines Panel. Coronavirus Disease 2019 (COVID-19) Treatment Guidelines. National Institutes of Health. Available at <https://www.covid19treatmentguidelines.nih.gov/>. Accessed [12 January 2021].
5. Wessels I, Rolles B, Rink L. The potential impact of zinc supplementation on COVID-19 pathogenesis. *Front Immunol*. 2020; 11:1712. <https://doi.org/10.3389/fimmu.2020.01712>
6. <https://pubmed.ncbi.nlm.nih.gov/?term=%28%28Zinc%29+AND+%28COVID-19%29%29+AND+%28treatment%29&sort=>
7. <https://www.newhope.com/market-data-and-analysis/market-overview-2020-supplement-sales-shift-changing-trends-and-refocused> [Accessed 12 Jan 2021]
8. <https://www.kktv.com/content/news/Zinc-sales-skyrocket-at-supplement-manufacturing-company-amid-pandemic-569900931.html> [Accessed 12 Jan 2021]
9. https://timesofindia.indiatimes.com/business/india-business/multivitamin-tops-drug-sales-for-1st-time-in-oct/articleshow/79768560.cms [Accessed 12 Jan 2021]
10. Read SA, Obeid S, Ahlenstiel C, Ahlenstiel G. The Role of Zinc in Antiviral Immunity. *Adv Nutr*. 2019 Jul 1;10(4):696-710. Doi: 10.1093/advances/nmz013. PMID: 31305906; PMCID: PMC6628855.
11. te Velthuis AJ, van den Worm SH, Sims AC, Baric RS, Snijder EJ, van Hemert MJ. Zn(2+) inhibits coronavirus and arterivirus RNA polymerase activity in vitro and zinc ionophores block the replication of these viruses in cell culture. *PLoS Pathog*. 2010;6(11):e1001176
12. Wessells, K. R., & Brown, K. H. (2012). Estimating the global prevalence of zinc deficiency: results based on zinc availability in national food supplies and the prevalence of stunting. *PLoS one*, 7(11): e50568
13. Prasad, AS, Brewer, GJ, Schoemaker, EB, et al. Hypocupremia Induced by Zinc Therapy in Adults. *JAMA*. 1978;240(20):2166-2168. Doi:10.1001/jama.1978.03290200044019
14. Nishime K, Kondo M, Saito K, Miyawaki H, Nakagawa T. Zinc Burden Evokes Copper Deficiency in the Hypoalbuminemic Hemodialysis Patients. *Nutrients*. 2020 Feb 23;12(2):577. Doi: 10.3390/nu12020577. PMID: 32102170; PMCID: PMC7071503.
15. Milton AH, Vashum KP, McEvoy M, Hussain S, McElduff P, Byles J, Attia J. Prospective Study of Dietary Zinc Intake and Risk of Cardiovascular Disease in Women. *Nutrients* 2018, 10, 38; doi:10.3390/nu10010038
16. Qu X, Yang H, Yu Z, Jia B, Qiao H, Zheng Y, Dai K. Serum zinc levels and multiple health outcomes: Implications for zinc-based biomaterials. *Bioact Mater*. 2020 Mar 31;5(2):410-422. Doi: 10.1016/j.bioactmat.2020.03.006

17. Worldometer. COVID-19 Coronavirus Pandemic. <https://www.worldometers.info/coronavirus/>
18. Max Roser, Hannah Ritchie, Esteban Ortiz-Ospina and Joe Hasell (2020) – “Coronavirus Pandemic (COVID-19)”. Published online at OurWorldInData.org. Retrieved from: ‘<https://ourworldindata.org/coronavirus>’ [Online Resource]
19. Singh S, Maurya RP, Singh RK. “Trained immunity” from Mycobacterium spp. Exposure or BCG vaccination and COVID-19 outcomes. *PloS Pathog.* 2020 Oct 29;16(10):e1008969. Doi: 10.1371/journal.ppat.1008969. PMID: 33119725.
20. Singh S. BCG Vaccines May Not Reduce Covid-19 Mortality Rates. medRxiv2020.04.11.20062232. <https://doi.org/10.1101/2020.04.11.20062232>
21. Escobara LE, Molina-Cruz A, Barillas-Mury C. BCG vaccine protection from severe coronavirus disease 2019 (COVID-19). *PNAS* 2020; 117: 17720-17726; www.pnas.org/cgi/doi/10.1073/pnas.2008410117
22. Singh S, Kaur R, Singh RK. Revisiting the role of vitamin D levels in the prevention of COVID-19 infection and mortality in European countries post infections peak. *Aging Clin Exp Res* 2020; 32:1609–1612 DOI: 10.1007/s40520-020-01619-8
23. Singh S. Covariation of Zinc Deficiency with COVID-19 Infections and Mortality in European Countries: Is Zinc Deficiency a Risk Factor for COVID-19? medRxiv; 2020. DOI: 10.1101/2020.06.12.20105676.
24. Arlehamna CSL, Settea A, Peters B. Lack of evidence for BCG vaccine protection from severe COVID-19. *PNAS* 2020; 117: 25203–25204; www.pnas.org/cgi/doi/10.1073/pnas.2016733117
25. Bao S, Knoell DL. Zinc modulates airway epithelium susceptibility to death receptor- mediated apoptosis. *American Journal of Physiology – Lung Cellular and Molecular Physiology.* 2006; 290:L433–L441.
26. World Health Organization. Zinc supplementation in children with respiratory infections e-Library of Evidence for Nutrition Actions (eLENA). World Health Organization (updated 11 February 2019) (https://www.who.int/elena/titles/zinc_pneumonia_children/en/; Accessed on 12 October 2020)
27. World Health Organization. Guideline: Nutritional care and support for patients with tuberculosis. Geneva: World Health Organization; 2013. ISBN: 978 92 4 150641 0 (https://apps.who.int/iris/bitstream/handle/10665/94836/9789241506410_eng.pdf;jsessionid=BE E74AC32E3B6835C757E6787332B883?sequence=1) https://www.who.int/nutrition/publications/guidelines/nutcare_support_patients_with_tb/en/)
28. Grobler L, Nagpal S, Sudarsanam TD, Sinclair D. Nutritional supplements for people being treated for active tuberculosis. *Cochrane Database of Systematic Reviews* 2016, Issue 6. Art. No.: CD006086. DOI: 10.1002/14651858.CD006086.pub4. [Accessed 14 January 2021]
29. Freiberg MS, Cheng DM, Gnatienco N, et al. Effect of Zinc Supplementation vs Placebo on Mortality Risk and HIV Disease Progression Among HIV-Positive Adults With Heavy Alcohol Use: A Randomized Clinical Trial. *JAMA Netw Open.* 2020;3(5):e204330. Doi:10.1001/jamanetworkopen.2020.4330
30. CDC. Your Health: People with Certain Medical Conditions. Centers for Disease Control and Prevention (CDC), U.S. Department of Health & Human Services, 2020 (Content source: National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral Diseases) (<https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-with-medical-conditions.html>; Updated 29 December 2020)
31. Brown KH. Effect of infections on plasma zinc concentration and implications for zinc status assessment in low-income countries. *Am J Clin Nutr* 1998;68(suppl):425S–9S.

32. Cabrera AJR. Zinc, aging, and immunosenescence: an overview. *Pathobiology of Aging & Age-related Diseases* 2015, 5: 25592 – <http://dx.doi.org/10.3402/pba.v5.25592>
33. Maret W. The redox biology of redox-inert zinc ions. *Free Radical Biology & Medicine*. 2019;134:311-326. DOI: 10.1016/j.freeradbiomed.2019.01.006.
34. Agnew UM, Slesinger TL. Zinc Toxicity. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2020 Jan-. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK554548/> [Updated 2020 May 7].




Fig. 1. Zinc sufficiency of the socially similar European populations correlated with COVID-19 mortality. Study populations: (A) Zn sufficiency estimates, (B) and (C) deaths and cases/million (26th April). [Note: Global maps [18] displayed color scheme variations performed using 'Inkscape']. Deaths (D) and cases (E) per million population positively correlated with their Zn sufficiency levels. (F) For the group of countries with different Zn sufficiency the interim case fatality ratio [i-CFR or Avg. CFR' = (reported deaths/ reported cases)*100] remained different throughout the period after peaking in May 2020. (G) Fold change in the relative CFR for high suff. with respect to low suff. countries has been registering steady increase while the gap for cases has kept shrinking.

CORRELATION ANALYSIS								
Data-Date	12 Mar	26 Mar	12 Apr	26 Apr	12 May	26 May	12 Jun	26 Jun
Average Deaths/Million Pop. ± STDEV	0.95 ± 3.50	17.61 ± 33.16	96.08 ± 121.08	158.70 ± 183.58	197.18 ± 221.29	213.49 ± 236.32	224.98 ± 246.55	230.11 ± 250.35
DEATHS/Million(Log) vs Zn SUFF. - Correlation $r(23)$:	0.3731	0.7893	0.7642	0.7455	0.7213	0.7099	0.6989	0.6849
p-value	0.0795	7.6E-06	2.19E-05	4.5E-05	0.0001	0.0001	0.0002	0.0003
Average Cases/million Pop. ± STDEV	84.10 ± 153.42	574.71 ± 778.36	1448.88 ± 1349.80	1936.17 ± 1569.23	2228.32 ± 1685.30	2390.92 ± 1747.82	2575.09 ± 1833.38	2736.12 ± 1943.94
CASES/Million (Log) vs Zn SUFF. - Correlation $r(23)$:	0.5658	0.6513	0.7681	0.7906	0.8067	0.8084	0.7966	0.7629
p-value	0.0049	0.0008	1.88E-05	7.1E-06	3.33E-06	3.05E-06	5.42E-06	2.3E-05

Table 1. Correlation Analysis of COVID-19 mortality and incidence with Zinc sufficiency of populations.

Correlation analysis for the most synchronized period of infections and response in twenty three socially similar European countries (highlighted yellow period – covers the rise and flattening of infections/mortality rate (see Supp. Datasheet). P-value <0.05 is referred to as statistically significant.